Bioengineered siRNA-Based Nanoplatforms Targeting Molecular Signaling Pathways for the Treatment of Triple Negative

Dima Hattab1, Athirah Bakhtiar2

  • 1School of Pharmacy, University of Jordan, Queen Rania Street, 11942 Amman, Jordan.

Pharmaceutics
|October 2, 2020
PubMed

Insights

Triple negative breast cancer (TNBC) treatment faces challenges due to its aggressive nature. Nanoparticle-delivered small interfering RNA (siRNA) offers a promising targeted therapeutic strategy to overcome these limitations.

Area of Science:

  • Oncology
  • Nanomedicine
  • Molecular Biology

Background:

  • Triple negative breast cancer (TNBC) lacks targeted therapies, necessitating novel treatment approaches.
  • Traditional chemotherapy for TNBC has limitations including cytotoxicity and resistance.
  • Small interfering RNA (siRNA) shows potential for gene silencing in TNBC but faces delivery challenges.

Purpose of the Study:

  • To review advances in siRNA-loaded nanotherapeutics for TNBC treatment.
  • To highlight the potential of nanotechnology in overcoming siRNA delivery obstacles.
  • To discuss the targeted therapeutic applications of siRNA-nanoparticles in TNBC.

Main Methods:

  • Review of preclinical and clinical studies on siRNA-loaded nanotherapeutics for TNBC.
  • Discussion of nanotechnology-based strategies for siRNA encapsulation and delivery.
  • Analysis of targeted signaling pathways affected by siRNA-nanoparticles.

Main Results:

  • Engineered siRNA-loaded nanotherapeutics demonstrate high efficiency and low toxicity in TNBC models.
  • Targeted delivery of siRNA via nanoparticles effectively inhibits tumor proliferation, invasion, metastasis, and angiogenesis.
  • siRNA-nanoparticles show potential in overcoming chemoresistance and modulating the tumor microenvironment.

Conclusions:

  • Nanotechnology-based siRNA delivery represents a promising strategy for TNBC therapy.
  • Targeted silencing of specific genes/pathways using siRNA-nanoparticles can enhance treatment efficacy.
  • Further development of siRNA-loaded nanotherapeutics holds significant potential for improving TNBC patient outcomes.